ClinicalTrials.gg
RecruitingNCT05433103BRAVe-MSUpdated Nov 18, 2026

Blood Flow Restriction And Veterans With MS

An interventional study of Low-Load Exercise with Blood Flow Restriction and Low-Load Exercise Control Group in Multiple Sclerosis, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Multiple Sclerosis by VA Office of Research and Development — 2 open to participants now, 2 under way, none of them phase 3. Multiple Sclerosis · VA Office of Research and Development.

Planned enrollment
6th of 17
58 · median 52
Started
2023
the only one that year
No phase
10 of 17
2 open now
Registered
16th of 17
by date

Among the 17 studies in Multiple Sclerosis by VA Office of Research and Development, this one is the 6th largest by planned enrollment, is the only one that started in 2023, is one of 10 with no phase, and was the 16th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 17 studies in Multiple Sclerosis by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Multiple Sclerosis by VA Office of Research and Development, or all of them as a file.
02

Study summary

There currently is a lack of evidence to support exercise interventions in people with advanced disability due to MS (i.e., need assistance to walk or use a wheelchair). This project proposes to study a strength training program using blood flow restriction (BFR) in people with advanced disability due to MS. BFR uses a device that partially blocks blood flow to the exercising limb and causes a response in the muscle which can replicate the effects of high-intensity training using much lower intensities. This is ideal for people with MS who have advanced disability, as they often cannot tolerate higher intensity exercise due to severe weakness and fatigue. By studying BFR training in people with advanced disability due to MS, the investigators hope to help improve strength, mobility, fatigue, and quality of life in people with MS. This study will target enrollment of Veterans with MS, who tend to have more advanced disability than non-Veterans with MS.

Read the detailed description

Multiple Sclerosis (MS) is a chronic neurological disorder affecting about 1 million Americans. Among the many MS symptoms, muscle weakness is among the most common, contributes to decreased mobility, and worsens as disability advances. While there is strong evidence that moderate-to-high intensity resistance training improves muscle strength in people with MS and low disability, there is little evidence evaluating resistance training in people with advanced disability due to MS (i.e., those who need assistance to walk or use a wheelchair). People with advanced disability due to MS require unique approaches to resistance training as they often cannot tolerate higher intensity exercise because of severe weakness and fatigue. Blood flow restriction (BFR) has the potential to address these issues. With BFR, resistance training at low intensities has been shown to be as effective as high intensity training without BFR at increasing muscle strength and hypertrophy in people with a variety of musculoskeletal conditions. The preliminary data supports the safety, feasibility, and tolerance of BFR resistance training in people with advanced disability due to MS. The objective of the currently proposed study is to evaluate the efficacy of low-load resistance training with BFR on muscle strength, mobility, and fatigue in people with advanced disability due to MS.

This proposed Phase II clinical trial will target enrollment of Veterans with MS, who would often have more severe symptoms, worse mobility, and more advanced disability compared to non-Veterans with MS. The study hopes to address a crucial gap that is highly relevant for Veterans with MS:

interventions to improve mobility and optimize function for those with advanced disability. Fifty-eight participants with MS and advanced disability will be randomized (1:1) to low-load resistance training with BFR (experimental) or without BFR (control). Resistance training will target knee and hip extension, knee and hip flexion, and ankle plantarflexion 2x/week for 10 weeks. A blinded assessor will collect outcomes at baseline, post- intervention (primary endpoint), and after 8 weeks of follow-up. The Study Aims are to determine between-group differences in 1) Muscle health: quadriceps strength (primary outcome) and muscle morphology (thickness and echogenicity); 2) Mobility: 30-Second Sit-to-Stand; and 3) Self-reported fatigue: Modified Fatigue Impact Scale. The investigators hypothesize that the experimental group will have significantly greater improvements in muscle strength and thickness, mobility, and self-reported fatigue compared to the control group. The long-term goal of this research is to develop clinically feasible exercise interventions for people with advanced disability due to MS that can improve participation, quality of life, and disability.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • Multiple Sclerosis
  • Blood Flow Restriction
  • Exercise
  • Low-load resistance training
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of MS
  2. Age 18-75
  3. Patient Determined Disease Steps (PDDS) 4 to 7

    • PDDS 4: Early cane: I use a cane or a single crutch or some other form of support (such as touching a wall or leaning on someone's arm) for walking all the time or part of the time, especially when walking outside. I think I can walk 25 feet in 20 seconds without a cane or crutch. I always need some assistance (cane or crutch) if I want to walk as far as three blocks.
    • PDDS 5: Late cane: To be able to walk 25 feet, I have to have a cane, crutch, or someone to hold onto. I can get around the house or other buildings by holding onto furniture or touching the walls for support. I may use a scooter or wheelchair if I want to go greater distances.
    • PDDS 6: Bilateral support: To be able to walk as far as 25 feet I must have two canes or crutches or a walker. I may use a scooter or wheelchair for longer distances.
    • PDDS 7: Wheelchair/scooter: My main form of mobility is a wheelchair. I may be able to stand and/or take one or two steps, but I can't walk 25 feet, even with crutches or a walker.

Exclusion criteria

Exclusion Criteria:

  1. PDDS 8: Unable to sit in a wheelchair for more than one hour.
  2. PDDS 3 or less: MS does not interfere with my activities, especially my walking. I can work a full day, but athletic or physically demanding activities are more difficult than they used to be. I usually don't need a can or other assistance to walk, but I might need some assistance during an attack.
  3. Moderate to Severe cognitive impairment as identified by the St. Louis University Mental Status Exam Score \<=20
  4. History of deep venous thrombosis/pulmonary embolism, peripheral vascular disease, thrombophilia, clotting disorders
  5. Systolic BP >= 180 mmHg or Diastolic BP >= 110 mmHg.
  6. Any comorbid conditions or pain that substantially affects physical function or would interfere with the participant's ability to safely complete rehabilitation (e.g. neurologic, vascular, cardiac problems, orthopedic, or ongoing medical treatments) as determined by a neurologist or physical therapist
  7. Patient report of easy bruising
  8. Severe lower extremity spasticity as defined as Modified Ashworth scale >2.
  9. Engaged in progressive resistance training program currently or in the previous 2 months prior to enrollment.
  10. Use of blood flow restriction currently or in the previous 2 months prior to enrollment.
  11. MS-related exacerbation or changes to their disease-modifying drug therapy in the month prior to enrollment.
  12. Inability to tolerate pressure cuff during baseline assessment.
  13. Unable to perform seated leg press exercise or no against gravity knee extension strength in at least one limb.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Low-Load Exercise with Blood Flow Restriction

    The BFR intervention will combine low-load resistance training with between 60%-80% blood flow occlusion under the supervision of a licensed physical therapist.

    Other: Low-Load Exercise with Blood Flow Restriction

  • Active comparator
    Low-Load Exercise Control

    The control group with consist only of low-load resistance training under the supervision of a licensed physical therapist.

    Other: Low-Load Exercise Control Group

Interventions

  • OtherLow-Load Exercise with Blood Flow Restriction

    Participants in the BFR group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training with at least 60% blood flow occlusion. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.

    Also known as: BFR

  • OtherLow-Load Exercise Control Group

    Participants in the Control group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.

    Also known as: Control

06

What researchers measure

Primary outcomes

  1. Quadriceps muscle strength

    Quadriceps muscle strength measured using dynamometry.

    Time frame: Change in muscle strength between Baseline (Week 0) and Primary Endpoint (Week 11)

Secondary outcomes

  1. Muscle morphology

    Muscle morphology is measured using ultrasonography to determine thickness and echogenicity.

    Time frame: Change between Baseline (Week 0) and Primary Endpoint (Week 11)

  2. 30-second sit to stand

    The number of times the participant can transition from sitting to standing in 30 seconds.

    Time frame: Change between Baseline (Week 0) and Primary Endpoint (Week 11)

  3. Modified Fatigue Impact Scale

    A 21-item questionnaire describing how fatigue may affect a person. Scores range from 0 to 84 with higher scores indicating more fatigue.

    Time frame: Change between Baseline (Week 0) and Primary Endpoint (Week 11)

Other outcomes

  1. Berg Balance Scale

    A test administered by a trained professional consisting of 14 predetermined tasks, each of which are scored on a scale from 0 to 4. Total scores range from 0 to 56 with higher scores indicating better balance.

    Time frame: Change between Baseline (Week 0) and Primary Endpoint (Week 11)

  2. Activity Monitor Sedentary Time

    Sedentary time is measured using an ActivPal device and is defined as time spent sitting, lying, or sleeping.

    Time frame: Change between Baseline (Week 0) and Primary Endpoint (Week 11)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Manago MM, Will R, Strahler T, Van Valkenburgh L, Harris-Love MO, Forster JE, Cameron M, Christiansen CL. Blood Flow Restriction and Veterans With Multiple Sclerosis and Advanced Disability: Protocol for a Randomized Controlled Trial. Phys Ther. 2024 Jun 4;104(6):pzae037. doi: 10.1093/ptj/pzae037. PubMed 38452199 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2027, 59 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 59 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2022
First posted
Jun 27, 2022
StartActual
Jan 1, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05433103
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Jan 1, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Mark M Manago, PT
Contact
mark.manago@va.gov
(303) 399-8020
Eliza A Biondi
Contact
eliza.biondi@va.gov
(303) 724-9170
Mark M Manago, PT
principal investigator · Rocky Mountain Regional VA Medical Center, Aurora, CO

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion